This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
474
Besifloxacin 0.6% administered into the study eye two times a day for three days.
Vehicle administered to the study eye two times a day for three days.
Bausch & Lomb Incorporated
Rochester, New York, United States
Clinical Resolution
The absence of both conjunctival discharge and bulbar conjunctival injection.
Time frame: Visit 2
Microbial Eradication
The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.
Time frame: Visit 2
Clinical Resolution
The absence of both conjunctival discharge and bulbar conjunctival injection.
Time frame: Visit 3
Microbial Eradication
The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.
Time frame: Visit 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.